AstraZeneca (AZN) Q4 2025 earnings review
Pipeline Delivers, But The Farxiga Cliff Arrives
AstraZeneca closed 2025 with Full Year Revenue up 8% and Core EPS up 11% (CER), successfully meeting guidance. However, Q4 revealed the friction of transition: Revenue growth slowed to 2% and Core EPS actually declined 2% due to a royalty buyout and lower margins. The narrative has shifted to a 'catalyst-rich' future to bridge the looming *Farxiga* patent expiry. With 2026 guidance forecasting 'low double-digit' EPS growth, management is betting heavily that new blockbusters (Enhertu, Tezspire) and 20+ upcoming Phase III readouts will outrun the drag from generics and China pricing pressure.
🐂 Bull Case
Oncology grew 17% in FY25, now comprising 44% of total revenue. Enhertu (+40%) and Tagrisso (+10%) continue to dominate, with Tagrisso effectively navigating Medicare Part D headwinds in the US.
AZN delivered 16 positive Phase III readouts in 2025 and expects 20+ more in 2026. This volume of late-stage assets (risk-adjusted peak sales >$10bn for 2026 readouts alone) provides multiple shots on goal to replace aging revenue streams.
🐻 Bear Case
Farxiga ($8.4bn revenue) faces Loss of Exclusivity (LOE) in the US in April 2026 and Volume-Based Procurement (VBP) in China immediately. This creates a massive revenue hole that puts immense pressure on new launches to perform perfectly.
Core Gross Margin fell 2pp to 80% and Operating Margin dropped 2pp to 26% in Q4. While partly due to a specific royalty buyout ($235m), it highlights the cost of securing future growth.
⚖️ Verdict: 🟢
Bullish. Despite the Q4 earnings dip and the looming patent cliff, the guidance for double-digit EPS growth in 2026 signals management's confidence. The density of the pipeline readouts offers significant upside optionality that outweighs the known generic risks.
Key Themes
Oncology: The Growth Engine
Oncology remains the primary driver, up 17% FY. Enhertu is a standout, growing 46% in Q4 alone. Tagrisso ($7.3bn FY) proved resilient against US pricing reforms. The strategy is deepening: moving existing drugs into earlier lines of therapy (e.g., Tagrisso into adjuvant settings) which significantly extends the duration of treatment and revenue tail.
The CVRM Transition Risk
Cardiovascular, Renal & Metabolism (CVRM) grew only 2% in FY25, a sharp deceleration. While Farxiga grew 9%, Brilinta collapsed 38% due to generics. The concern is that Farxiga—the segment's anchor—hits the 'patent cliff' in 2026. Management is pivoting to next-gen assets like baxdrostat (HTN) and oral GLP-1s, but there is a timing gap between Farxiga's decline and these new assets contributing meaningful revenue.
Weight Management: Oral GLP-1 Entry
AZN is aggressively entering the obesity space, not with 'me-too' injectables, but with oral small molecules. Phase II data for their oral GLP-1 (elecoglipron) was positive, triggering Phase III initiation. They also licensed a preclinical long-acting injectable from CSPC (China). This is a high-risk, high-reward play to compete with Novo/Lilly by focusing on oral convenience and combinations (e.g., with SGLT2s) for comorbidity management rather than just cosmetic weight loss.
China: Volume vs. Price Trade-off
China revenue grew 4% in FY25 (CER), but the environment is hardening. The company faces immediate VBP (Volume-Based Procurement) price cuts for Farxiga and others in Q1 2026. Management claims volume gains and new launches (Enhertu, Breztri) will offset price erosion, but margins in China are structurally lower than the group average. The 'growth at any cost' model in China is being tested.
Datopotamab Deruxtecan (Dato-DXd) Uncertainty
While touted as a major driver, the Dato-DXd narrative is mixed. Sales were only $40m in Q4. The TROPION-Lung12 trial was discontinued for 'feasibility,' and US regulatory strategy has shifted. This asset was supposed to be the 'next Enhertu,' but clinical and regulatory friction suggests a slower or more niche rollout than initially hyped.
Q4 Profitability Miss
Q4 Core EPS of $2.12 (-2% CER) missed the trajectory set in Q3 (+27%). This was driven by a 2pp drop in Gross Margin to 80%, largely due to a $235m royalty buyout expense. While this buyout improves future margins (eliminating royalties on Saphnelo), the immediate hit dampened the quarter's quality.
Other KPIs
Accelerating. Up 12% CER vs prior year. R&D intensity remains high at 24% of revenue. This elevated spend is non-negotiable to support the 100+ Phase III trials active, but it caps near-term operating margin expansion.
Stable. Up 4% CER. Ultomiris (+19%) has largely cannibalized Soliris (-28%), completing the franchise switch. This segment provides stable cash flow but is no longer a high-growth engine compared to Oncology.
Decelerating. Up 5% CER. Growth is being weighed down by the decline in V&I (Vaccines & Immune Therapies) and the maturation of CVRM assets. Respiratory (R&I) remains healthy at +12%.
Guidance
Accelerating vs Q4 2025 (+2%), effectively maintaining the FY25 pace (+8%). This assumes new products (Enhertu, Tezspire, Airsupra) can fully offset the multi-billion dollar headwind from Farxiga generic entry in the US.
Reversing. A sharp pivot from the -2% decline seen in Q4 2025. Management expects operating leverage and the removal of one-off costs (like the Q4 royalty buyout) to restore profit growth despite the revenue headwinds.
Stable. Consistent with the 18% seen in FY25, indicating no major tax headwinds are expected to impact the bottom line.
Key Questions
Bridge Over the Farxiga Cliff
With Farxiga losing US exclusivity in April and facing China VBP, precisely which 2-3 assets do you model as the primary offset in H2 2026 to maintain mid-to-high single digit growth? Is the guidance back-end loaded?
Dato-DXd Lung Strategy
Given the mixed data in lung cancer and trial discontinuations (TROPION-Lung12), have you revised the peak sales expectations for Dato-DXd downwards, or shifted the primary opportunity to breast cancer?
Obesity Market Differentiation
You are entering the obesity market significantly behind leaders. With oral GLP-1s moving to Phase III, how do you differentiate clinically against established injectables and upcoming oral competitors? Is the strategy purely combination-based?
China Profitability
You mentioned China volume growth offsetting price cuts. However, with VBP impacting major franchises, what is the trajectory for China *margins* specifically? Are we trading profitable revenue for lower-quality volume?